Curevac chief technology officer to pursue new career outside biotech industry

TÜbingen, germany and boston, ma / accesswire / january 17, 2022 / curevac n.v. (nasdaq:cvac), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mrna"), today announced that the company's chief technology officer, dr. mariola fotin-mleczek, will resign from curevac effective january 31, 2022.
CVAC Ratings Summary
CVAC Quant Ranking